Infectious Diseases Research and Development Act of 2005

H.R. 3154, the Infectious Diseases Research and Development Act of 2005, proposes a series of financial and regulatory incentives to encourage the development of new treatments for infectious diseases. The bill would limit the legal liability of drug manufacturers by capping non-economic damages at $250,000 and restricting punitive damages in lawsuits related to these products. Additionally, the legislation offers tax credits for research and manufacturing, extends patent protections for certain drugs, and creates a "fast-track" approval process at the FDA to bring new antibiotics and treatments to market more quickly.

For the average citizen, this bill aims to increase the availability of new medicines to fight drug-resistant infections and public health threats. While these measures are designed to lower the costs and risks for companies developing life-saving drugs, the bill would also limit the amount of compensation patients or their families could recover in court if they are harmed by one of these products. Finally, the bill establishes a national commission to identify the most dangerous pathogens and directs federal resources toward helping smaller companies conduct the clinical trials necessary to prove their treatments are safe and effective.